SRR1374414
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.598
- TNFA_SIGNALING_VIA_NFKB+0.481
- HYPOXIA+0.448
- P53_PATHWAY+0.403
- INFLAMMATORY_RESPONSE+0.393
- MTORC1_SIGNALING+0.389
- PANCREAS_BETA_CELLS+0.375
- IL6_JAK_STAT3_SIGNALING+0.355
- COAGULATION+0.354
- ESTROGEN_RESPONSE_EARLY+0.347
Top 10 suppressed
- G2M_CHECKPOINT-0.346
- E2F_TARGETS-0.343
- MITOTIC_SPINDLE-0.310
- DNA_REPAIR-0.298
- WNT_BETA_CATENIN_SIGNALING-0.231
- PROTEIN_SECRETION-0.193
- MYC_TARGETS_V2-0.137
- UV_RESPONSE_DN-0.130
- SPERMATOGENESIS-0.028
- HEDGEHOG_SIGNALING-0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1347688 | GTEX | — | 0.948 |
| 2 | SRR1488349 | GTEX | — | 0.944 |
| 3 | SRR1440356 | GTEX | — | 0.932 |
| 4 | SRR820518 | GTEX | — | 0.930 |
| 5 | SRR1323196 | GTEX | — | 0.916 |
| 6 | SRR1335688 | GTEX | — | 0.913 |
| 7 | SRR663693 | GTEX | — | 0.909 |
| 8 | SRR1355595 | GTEX | — | 0.909 |
| 9 | SRR1445514 | GTEX | — | 0.908 |
| 10 | SRR820256 | GTEX | — | 0.897 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.598 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.481 | Inavolisib | — uncovered |
| HYPOXIA | 0.448 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.403 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.393 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.389 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.375 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.355 | Inavolisib | — uncovered |
| COAGULATION | 0.354 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.347 | Inavolisib | — uncovered |
| APOPTOSIS | 0.331 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.328 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.327 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.319 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.307 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.298 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.289 | Inavolisib | — uncovered |
| MYOGENESIS | 0.289 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.285 | Remibrutinib | — uncovered |